Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 14, 2014, Pages 1437-1444

  Miller, Kathy D ^a   Diéras, Véronique ^f   Harbeck, Nadia ^h,i   Andre, Fabrice ^g   Mahtani, Reshma L ^b   Gianni, Luca ^j   Albain, Kathy S ^c   Crivellari, Diana ^k   Fang, Liang ^d   Michelson, Glenn ^d   De Haas, Sanne L ^l   Burris, Howard A ^e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d GENENTECH INC   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f INSTITUT CURIE   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j SAN RAFFAELE HOSPITAL   (Italy)

^k CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; BREAST METASTASIS; CANCER LOCALIZATION; CANCER SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED ANEMIA; CHILL; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATURIA; HUMAN; INFUSION RELATED REACTION; INSOMNIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEUTROPENIA; PERIPHERAL SENSORY NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BLEEDING; VOMITING; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROTO ONCOGENE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-2; HUMANS; KAPLAN-MEIER ESTIMATE; MAYTANSINE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 84902973417     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.6590     Document Type: Article

References (29)

1. Lewis Phillips GD, Li G, Dugger DL, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290, 2008
2. Hurvitz SA, Dirix L, Kocsis J, et al: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157-1163, 2013
3. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
4. Wildiers H, Kim S-B, Gonzalez-Martin A, et al: T-DM1 for HER2-positive metastatic breast cancer (MBC): Primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice. Presented at the European Cancer Congress 2013, Amsterdam, Netherlands, September 27-October 1, 2013 (abstr LBA-15)
5. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004
6. Adams CW, Allison DE, Flagella K, et al: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717-727, 2006
7. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
8. Swain SM, Kim SB, Cortés J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461-471, 2013
9. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
10. Phillips GD, Fields CT, Li G, et al: Dual targeting of HER2-positive cancer with trastuzumabemtansine (T-DM1) and pertuzumab: Critical role for neuregulin blockade in anti-tumor response to combination therapy. Clin Cancer Res 20:456-468, 2014
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
13. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, openlabel, multicentre, phase 3 trial. Lancet 379:633-640, 2012
14. Blackwell KL, Burstein HJ, Storniolo AM, et al: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 study. J Clin Oncol 30:2585-2592, 2012
15. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
16. Ellis P, Barrios C, Im YH, et al: MARIANNE: A phase III, randomized, multicenter study of trastuzumab emtansine (T-DM1) ± pertuzumab compared with trastuzumab plus taxane for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive, progressive or recurrent locally advanced or metastatic breast cancer. J Clin Oncol 29:7s, 2011 (suppl; abstr TPS102)
17. Krop IE, LoRusso P, Miller KD, et al: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234-3241, 2012
18. Burris HA III, Rugo HS, Vukelja SJ, et al: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29: 398-405, 2011
19. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138-1144, 2010
20. Perez EA, Hurvitz SA, Amler LC, et al: Exploratory analysis of the relationship between HER2 expression (by qRT-PCR) and efficacy with first-line trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel in a randomized phase 2 study of patients with HER2-positive MBC. Ann Oncol 23:ix89, 2012 (suppl, abstr 226P)
21. Baselga J, Verma S, Ro J, et al: Relationship between tumor biomarkers and efficacy in EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. Presented at the American Association for Cancer Res Annual Meeting, Washington DC, April 6-10, 2013 (abstr LB-63)
22. Agus DB, Sweeney CJ, Morris MJ, et al: Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castrationresistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25:675-681, 2007
23. Herbst RS, Davies AM, Natale RB, et al: Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 13:6175-6181, 2007
24. Gordon MS, Matei D, Aghajanian C, et al: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324-4332, 2006
25. Lenihan D, Suter T, Brammer M, et al: Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 23:791-800, 2012
26. Swain SM, Ewer MS, Cortés J, et al: Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study. Oncologist 18:257-264, 2013
27. Krop IE, Beeram M, Modi S, et al: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704, 2010
28. Mahapatra K, Darbonne WC, Bumbaca D, et al: T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner. Mol Cancer Ther 10, 2011 (abstr A135)
29. Bender BC, Schaedeli-Stark F, Koch R, et al: A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 70: 591-601, 2012